Efficacy of statin therapy in reducing epicardial adipose tissue: a systematic review and meta-analysis

Tannaz Jamialahmadi[1,2], Luis E. Simental-Mendia[3], Ali H. Eid[4], Wael Almahmeed[5], Sepideh Salehabadi[2], Khalid Al-Rasadi[6], Maciej Banach[7,8], Amirhossein Sahebkar[9,10,11]

[1]Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
[2]Medical Toxicology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
[3]Biomedical Research Unit, Mexican Social Security Institute, Durango, Mexico
[4]Department of Basic Medical Sciences, College of Medicine, QU Health, Qatar University, Doha, Qatar
[5]Heart and Vascular Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates
[6]Medical Research Centre, Sultan Qaboos University, Muscat, Oman
[7]Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL) Lodz, Poland.
[8]The Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD, USA
[9]Center for Global Health Research, Saveetha Medical College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, India
[10]Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
[11]Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

Corresponding author:
Prof. Amirhossein Sahebkar
Biotechnology Research
Center
Pharmaceutical
Technology Institute
Mashhad University
of Medical Sciences
Mashhad, Iran
E-mail: amir_saheb2000@
yahoo.com

Abstract

Introduction: Understanding the effect of statins on epicardial adipose tissue (EAT) is important as it may help reduce the negative impact of EAT-derived molecules on the cardiovascular system and consequently on coronary artery disease. Thus, we aimed to perform a systematic review and meta-analysis to assess the impact of statin therapy on EAT.
Methods: The study utilized Scopus, PubMed, Embase, and Web of Science to gather relevant studies on the impacts of statins on EAT until September 5th, 2023. The data collected underwent meta-analysis using Comprehensive Meta-Analysis (CMA) V4 software.
Results: In the meta-analysis, three studies involving 512 subjects were ultimately incorporated. The findings indicated a significant decrease in EAT after treatment with statins (standardized mean difference (SMD = −0.507, 95% CI: −2.536, 1.521, p = 0.021).
Conclusions: Statins appear to exert an additional cardiovascular therapeutic effect by reducing EAT.

Key words: epicardial adipose tissue, cardiovascular disease, coronary artery disease, statin, systematic review.

Epicardial adipose tissue (EAT), the visceral fat surrounding the heart, has recently emerged as a significant player in the pathophysiology of

AMS

Tannaz Jamialahmadi, Luis E. Simental-Mendia, Ali H. Eid, Wael Almahmeed, Sepideh Salehabadi, Khalid Al-Rasadi, Maciej Banach, Amirhossein Sahebkar

cardiovascular diseases (CVD) [1]. EAT is not just a storage site for energy, but is rather an active endocrine and paracrine organ that secretes several bioactive molecules, collectively referred to as adipocytokines [2]. These adipocytokines have been implicated in the development and progression of atherosclerosis, insulin resistance, and other CVD risk factors [3]. Statins, widely prescribed for their lipid-lowering properties despite the introduction of newer lipid-lowering agents [4–6], have shown remarkable pleiotropic effects beyond their primary cholesterol-lowering capabilities [7–12]. These effects encompass anti-inflammatory, antioxidant, anti-thrombotic, and endothelial function-improving properties [7–14]. Given the growing recognition of EAT as a relevant contributor to CVD [15], investigating the impact of statin therapy on EAT characteristics has become a topic of great interest. Understanding the influence of statin therapy on EAT holds significant clinical implications [16]. By modulating the properties of EAT, statins may potentially attenuate the adverse effects of EAT-derived adipocytokines on the cardiovascular system [17]. Moreover, considering the anatomical proximity of EAT to the coronary arteries, statin-induced changes in EAT may have direct implications for the development and progression of coronary artery disease [11, 18, 19]. To comprehensively evaluate the impact of statin therapy on EAT, a systematic review and meta-analysis are warranted. Such an analysis can consolidate the existing evidence, assess the consistency of findings across studies, and provide a quantitative estimation of the effect size.

Therefore, this study aimed to conduct a systematic review and meta-analysis to investigate the impact of statin therapy on EAT.

Methods. *Search strategy.* The current study was performed according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines [20]. PubMed, Web of Science, Scopus, ClinicalTrials.gov, and Google Scholar databases were used for the following search terms in titles and abstracts: ("statin" or "HMG-CoA reductase inhibitor" OR "lipid lowering agents" OR "Atorvastatin" OR "Pravastatin" OR "Fluvastatin" OR "Simvastatin" OR "Rosuvastatin" OR "Lovastatin" OR "Pitavastatin") AND (epicardial adipose tissue OR epicardial fat). The wild-card term "*" was used to improve the sensitivity of the search strategy. The search was performed from inception to September 5th, 2023.

Study selection. Clinical studies were included if they met the following inclusion criteria: (i) trials investigating the effect of statin on EAT, (ii) presentation of enough information at baseline and following therapy in patients providing the net change values. Also, exclusion criteria were: (i) no sufficient information at baseline or follow-up, (ii) case studies or reviews, (iii) non-English studies.

Data extraction. The authors conducted a data extraction process by removing duplicate studies. Two independent and blinded evaluators screened the titles and abstracts of the remaining publications for eligibility. We obtained and reviewed complete reports of studies that were potentially eligible, with any discrepancies being settled through discussion with a third author until a consensus was reached. The eligible studies were then reviewed, and data such as the first author information, publication date, design of the study, type of statin used, dosage of statin, treatment duration, patient information, and outcome were abstracted.

Quality assessment. To determine the quality of the studies in this meta-analysis, the Cochrane guidelines were followed. The risk of bias was evaluated based on various factors such as selection bias, detection bias, performance bias, attrition bias, reporting bias, and other sources of bias. Each of the included studies was assessed to be either high, low or unclear in terms of these biases.

Quantitative data synthesis. The Comprehensive Meta-Analysis (CMA) V4 software [21] was utilized to conduct a meta-analysis, where standardized mean differences (SMDs) were calculated based on sample size, means, and standard deviations from each group. To account for study

Table I. Demographic characteristics of the included studies

Author	Study design	Target population	Treatment duration	N	Measurement of EAT	Study groups
Nerlekar *et al.* 2020 [31]	Randomized controlled trial	Coronary atherosclerosis	4.3 years	54 36	CT coronary angiography	Statin treatment Control
Raggi *et al.* 2019 [16]	Randomized, double-blind, controlled	Postmenopausal women	52 weeks	194 226	CT imaging	Atorvastatin 80 mg/day Pravastatin 40 mg/day
Soucek *et al.* 2015 [32]	Randomized, double-blind, placebo-controlled	Atrial fibrillation	12 weeks	38 41	CT imaging	Atorvastatin 80 mg/day Placebo

EAT – epicardial adipose tissue.

design, treatment duration, and population characteristics, a random-effects model (using the Der Simonian-Laird method) and the generic inverse variance weighting method were used [22]. The effect sizes were shown as SMD and 95% confidence interval (CI).

Results. *Study selection process.* Briefly, 75 papers were initially obtained following the search through the aforementioned databases; 65 of these were excluded upon reviewing the titles and abstracts. Next, 9 full-text articles were checked and six were discarded for duplicate reports ($n = 1$) and incomplete data ($n = 5$). Thus, three studies were included in this meta-analysis (Table I). The study selection process is presented in Figure 1.

Effects of statins on EAT in RCTs. The meta-analysis of three trials including 512 patients sug-

gested a significant reduction in EAT after statin treatment (SMD = −0.507, 95% CI: −2.536, 1.521, $p = 0.021$) (Figure 2).

Quality assessment. Risk of bias in this meta-analysis was evaluated based on the Cochrane instructions [23] (Table II).

Discussion. Based on the findings of our meta-analysis, it is evident that the use of statins as a treatment option might lead to a significant reduction in EAT. It is important to note that excessive EAT has been linked to an increased risk of cardiometabolic complications, as well as fatal and non-fatal coronary events [15, 16]. Therefore, reducing the harmful consequences associated with excessive EAT could potentially aid in CVD prevention. While previous research has demonstrated the positive impact of lifestyle modifications such as diet and exercise, as well as bar-


**Figure 1.** Flow chart of the number of studies selected for meta-analysis

Figure 2. Meta-analysis of the effects of statins on EAT in RCTs

Table II. Quality of bias assessment of the included studies according to the Cochrane guidelines

Study	Sequence generation	Allocation concealment	Blinding of participants, personnel and outcome assessors	Incomplete outcome data	Selective outcome reporting	Other sources of bias
Nerlekar *et al.* 2020 [31]	L	U	H	L	L	U
Raggi *et al.* 2019 [16]	U	U	U	L	L	U
Soucek *et al.* 2015 [32]	L	L	U	L	L	L

L – low risk of bias, H – high risk of bias, U – unclear risk of bias.

Tannaz Jamialahmadi, Luis E. Simental-Mendia, Ali H. Eid, Wael Almahmeed, Sepideh Salehabadi, Khalid Al-Rasadi, Maciej Banach, Amirhossein Sahebkar

iatric surgery, on reducing EAT [24, 25], there are currently no pharmacological interventions specifically designed for EAT reduction. To date, lipid-lowering drugs such as statins have been tested as potential treatments for reducing EAT. Intensive statin therapy has shown a beneficial effect on reducing EAT, and this effect seems to be dose-dependent [13]. Importantly, this reduction in EAT is not solely due to the lipid-lowering properties of statins [16]. Parisi *et al.* suggested that statins may have anti-inflammatory properties that directly correlate with the thickness of EAT and can reduce inflammation in cultured EAT adipocytes [17]. Additionally, statins may affect EAT thickness through the modulation of peroxisome proliferator-activated receptors (PPARs) [26]. However, our meta-analysis revealed a significant but small impact of statins on reducing EAT. Our research findings may support the concept that atherosclerosis is not solely an issue within the blood vessels, but a disease that may also affect perivascular tissues [27, 28]. Evidence suggests that lipids may "invade" the inner layer of the vasa vasorum [27–29]. Furthermore, recent studies indicated that intensive lipid-lowering treatment can reduce the presence of vasa vasorum around the carotid artery in humans [13]. Recently, there has been growing interest in considering EAT as a potential target for therapeutic interventions aimed at modifying adipose tissue [30]. It is crucial to thoroughly investigate the mechanisms behind the abnormal accumulation of EAT in order to develop innovative and effective therapies that specifically target this tissue. We acknowledge several potential limitations in our study. Firstly, the diagnosis of EAT was determined using various imaging techniques in the analyzed publications. However, we used SMD to combine the results from various diagnostic approaches. Secondly, there was a high degree of statistical heterogeneity among the included studies. Nevertheless, the results remained consistent when sensitivity analysis was performed. Lastly, the follow-up duration varied across the analyzed studies.

In conclusion, statins may have additional potential benefits beyond lowering plasma LDL-C levels. Here, we showed how these drugs can potentially exert a therapeutic effect by mitigating EAT. However, further research is necessary to establish standardized methods for quantifying and identifying normal EAT values, as well as to enhance our knowledge of the cellular and molecular processes that lead to EAT dysregulation. Finally, it remains to be clarified whether the reducing effect on EAT is a function of the intensity of statin therapy.

Funding

Ethical approval

Not applicable.

Conflict of interest

The authors declare no conflict of interest.

References

1. van Woerden G, Gorter TM, Westenbrink BD, Willems TP, van Veldhuisen DJ, Rienstra M. Epicardial fat in heart failure patients with mid-range and preserved ejection fraction. Eur J Heart Failure 2018; 20: 1559-66.
2. Talman AH, Psaltis PJ, Cameron JD, Meredith IT, Seneviratne SK, Wong DTL. Epicardial adipose tissue: far more than a fat depot. Cardiovasc Diagn Ther 2014; 4: 416-29.
3. Al Zein M, Zein O, Diab R, et al. Intermittent fasting favorably modulates adipokines and potentially attenuates atherosclerosis. Biochem Pharmacol 2023; 218: 115876.
4. Banach M, Reiner Z, Cicero AFG, et al. The year in cardiovascular disease – the year of upfront lipid lowering combination therapy. Arch Med Sci 2022; 18: 1429-34.
5. Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013; 2013: CD004816.
6. Banach M, Surma S. A look to the past – what has had the biggest impact on lipids in the last four decades? A personal perspective. Arch Med Sci 2023; 19: 559-64.
7. Chamani S, Liberale L, Mobasheri L, et al. The role of statins in the differentiation and function of bone cells. Eur J Clin Invest 2021; 51: e13534.
8. Vahedian-Azimi A, Beni FH, Fras Z, et al. Effects of statins on the incidence and outcomes of acute kidney injury in critically ill patients: a systematic review and meta-analysis. Arch Med Sci 2023; 19: 952-64.
9. Vahedian-Azimi A, Mannarino MR, Shojaie S, et al. Effect of statins on prevalence and mortality of influenza virus infection: a systematic review and meta-analysis. Arch Med Sci 2022; 18: 1513-24.
10. Vahedian-Azimi A, Mohammadi SM, Banach M, et al. Improved COVID-19 outcomes following statin therapy: an updated systematic review and meta-analysis. BioMed Res Int 2021; 2021: 1901772.
11. Mollazadeh H, Tavana E, Fanni G, et al. Effects of statins on mitochondrial pathways. J Cachexia Sarcopenia Muscle 2021; 12: 237-51.
12. Sahebkar A, Kiaie N, Gorabi AM, et al. A comprehensive review on the lipid and pleiotropic effects of pitavastatin. Prog Lipid Res 2021; 84: 101127.
13. German CA, Liao JK. Understanding the molecular mechanisms of statin pleiotropic effects. Arch Toxicol 2023; 97: 1529-45.
14. Bahrami A, Parsamanesh N, Atkin SL, Banach M, Sahebkar A. Effect of statins on toll-like receptors: a new insight to pleiotropic effects. Pharmacol Res 2018; 135: 230-8.
15. Fang W, Xie S, Deng W. Epicardial adipose tissue: a potential therapeutic target for cardiovascular diseases. J Cardiovasc Transl Res 2024; 17: 322-33.
16. Raggi P, Gadiyaram V, Zhang C, Chen Z, Lopaschuk G, Stillman AE. Statins reduce epicardial adipose tissue attenuation independent of lipid lowering: a potential pleiotropic effect. J Am Heart Assoc 2019; 8: e013104.

17. Parisi V, Petraglia L, D'Esposito V, et al. Statin therapy modulates thickness and inflammatory profile of human epicardial adipose tissue. Int J Cardiol 2019; 274: 326-30.

18. El Shahawy ES, Hassan AA, El Shahawy MS. Epicardial fat volume as a good predictor for multivessel coronary artery disease. High Blood Press Cardiovasc Prev 2023; 30: 427-34.

19. Fan W, Si Y, Xing E, et al. Human epicardial adipose tissue inflammation correlates with coronary artery disease. Cytokine 2023; 162: 156119.

20. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009; 62: 1006-12.

21. Borenstein M. Comprehensive meta-analysis software. In: Systematic Reviews in Health Research: Meta-analysis in Context. Egger M, Higgins JPT, Davey Smith D (eds.). 2022; 535-48.

22. Sutton AJ, Abrams KR, Sheldon TA, Song F, Jones DR. Methods for Meta-analysis in Medical Research. Wiley Chichester 2000.

23. Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration. London, UK 2011.

24. Kahl K, Kerling A, Tegtbur U, et al. Effects of additional exercise training on epicardial, intra-abdominal and subcutaneous adipose tissue in major depressive disorder: a randomized pilot study. J Affective Disord 2016; 192: 91-7.

25. Graziani F, Leone AM, Cialdella P, et al. Effects of bariatric surgery on cardiac remodeling: clinical and pathophysiologic implications. Eur Heart J 2013; 34 (Suppl 1): 4356.

26. Myasoedova VA, Parisi V, Moschetta D, et al. Efficacy of cardiometabolic drugs in reduction of epicardial adipose tissue: a systematic review and meta-analysis. Cardiovasc Diabetol 2023; 22: 23.

27. Stary HC, Blankenhorn DH, Chandler AB, et al. A definition of the intima of human arteries and of its atherosclerosis-prone regions. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler Thromb Vasc Biol 1992; 12: 120-34.

28. Moreno PR, Purushothaman KR, Sirol M, Levy AP, Fuster V. Neovascularization in human atherosclerosis. Circulation 2006; 113: 2245-52.

29. Takase H, Dohi Y, Okado T, Hashimoto T, Goto Y, Kimura G. Effects of ezetimibe on visceral fat in the metabolic syndrome: a randomised controlled study. Eur J Clin Investig 2012; 42: 1287-94.

30. Iacobellis G, Sharma AM. Epicardial adipose tissue as new cardio-metabolic risk marker and potential therapeutic target in the metabolic syndrome. Curr Pharm Design 2007; 13: 2180-4.

31. Nerlekar N, Thakur U, Lin A, et al. The Natural history of epicardial adipose tissue volume and attenuation: a long-term prospective cohort follow-up study. Sci Rep 2020; 10: 7109.

32. Soucek F, Covassin N, Singh P, et al. Effects of atorvastatin (80 mg) therapy on quantity of epicardial adipose tissue in patients undergoing pulmonary vein isolation for atrial fibrillation. Am J Cardiol 2015; 116: 1443-6.